case_images: PMC6332900_01
case_images: Time course of laboratory parameters and treatments. Panels a and b show changes in bio-chemical parameters and coagulation factors. Note that after the supplementation of ATIII concentrate, AST and ALT (a) remarkably decreased with associations of PT and PLT (b) improvements. CRP (a) did not respond despite high IL-6 levels (a), after ATIII concentrate, unexpectedly increased, which might show a possible improvement in hepatic CRP synthesis. Panels c and d demonstrate prominent elevations in TAT (c), FDP and PIC (d) in the early phase, which was accompanied with a steep drop in alpha2PI (d). tPAI-1 (d) increased gradually, peaking on day 3, which was followed by a sustained SF (c) soaring. Although TAT dropped gradually, SF augmentation was not attenuated. After the combined administration of rh-TM-alpha and ATIII concentrate, further decrease in TAT with a gradual fall in SF occurred, along with changes in bio-chemical parameters stated above
case_images: 40560_2019_359_Fig1_HTML.jpg
case_images: PMC6332900_01_40560_2019_359_Fig1_HTML.jpg
case_images: Fig1
case_images: His procalcitonin level was low (0.087 ng/mL, Fig. 1a), and the bacteriological examinations showed no evident infection. We administered 1000 mg of tranexamic acid and transfused fresh frozen plasma (FFP) with concentrated platelets (upper portion of the Fig. 1). Therefore, we administered rh-TM-alpha (130 U/kg/day) for the purpose of anticoagulation from day 3 (upper portion of Fig. 1). We therefore added ATIII concentrate at an initial loading of 1500 U for 3 h followed by a continuous infusion of 1500 U/day for 3 days (upper portion of Fig. 1).